Activation of AMP-Activated Protein Kinase by Metformin Improves Left Ventricular Function and Survival in Heart Failure
- 13 February 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation Research
- Vol. 104 (3), 403-411
- https://doi.org/10.1161/circresaha.108.190918
Abstract
Clinical studies have reported that the widely used antihyperglycemic drug metformin significantly reduces cardiac risk factors and improves clinical outcomes in patients with heart failure. The mechanisms by which metformin exerts these cardioprotective effects remain unclear and may be independent of antihyperglycemic effects. We tested the hypothesis that chronic activation of AMP-activated protein kinase (AMPK) with low-dose metformin exerts beneficial effects on cardiac function and survival in in vivo murine models of heart failure. Mice were subjected to permanent left coronary artery occlusion or to 60 minutes left coronary artery occlusion followed by reperfusion for 4 weeks. High-resolution, 2D echocardiography was performed at baseline and 4 weeks after myocardial infarction to assess left ventricular dimensions and function. Metformin (125 μg/kg) administered to mice at ischemia and then daily improved survival by 47% (PP<0.01 versus vehicle) at 4 weeks. The improvement in cardiac structure and function was associated with increases in AMPK and endothelial nitric oxide synthase (eNOS) phosphorylation, as well as increased peroxisome proliferator-activated receptor-γ coactivator (PGC)-1α expression in cardiac myocytes. Furthermore, metformin significantly improved myocardial cell mitochondrial respiration and ATP synthesis compared to vehicle. The cardioprotective effects of metformin were ablated in mice lacking functional AMPK or eNOS. This study demonstrates that metformin significantly improves left ventricular function and survival via activation of AMPK and its downstream mediators, eNOS and PGC-1α, in a murine model of heart failure.Keywords
This publication has 42 references indexed in Scilit:
- Acute Metformin Therapy Confers Cardioprotection Against Myocardial Infarction Via AMPK-eNOS–Mediated SignalingDiabetes, 2008
- European PerspectivesCirculation, 2008
- Metformin in Heart FailureDiabetes Care, 2007
- Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial functionProceedings of the National Academy of Sciences of the United States of America, 2007
- Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic reviewBMJ, 2007
- AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1αProceedings of the National Academy of Sciences of the United States of America, 2007
- AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase BAmerican Journal of Physiology-Heart and Circulatory Physiology, 2006
- Role of AMP-activated protein kinase in mechanism of metformin actionJCI Insight, 2001
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Mitochondrial abnormalities in myocardium of dogs with chronic heart failureJournal of Molecular and Cellular Cardiology, 1992